TELA Bio Q2 Revenue Seen Dipping 0.9% to $20M, Loss at $0.18; New CEO Named
TELA sits 74% above its 52-week low of $0.501.
Summary
TELA Bio's Q2 2026 revenue is expected around $20.0M, a 0.9% year-over-year decline, with a projected loss of $0.18 per share. This follows a Q1 where revenue grew only 3% and losses widened, pushing stockholders' equity negative. The company also installed Heather Getz as CEO effective August 3-4, replacing Antony Koblish who resigned from the board. Getz brings experience from Butterfly Network, but the equity package granted equals ~6.3% of outstanding shares, adding dilution pressure. With the stock at $0.87 and a market cap under $40M, the persistent losses and leadership overhaul signal ongoing distress.
At the time of this announcement, TELA was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.9M. The 52-week trading range was $0.50 to $2.14. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.